tailieunhanh - Báo cáo y học: "Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical response"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học General Psychiatry cung cấp cho các bạn kiến thức về ngành y đề tài: Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical response. | Available online http content 11 4 R131 Research article Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis depletion of memory B cells correlates with clinical response Magda Nakou1 Georgios Katsikas1 Prodromos Sidiropoulos1 George Bertsias1 Eva Papadimitraki1 Amalia Raptopoulou1 Helen Koutala2 Helen A Papadaki3 Herakles Kritikos1 and Dimitrios T Boumpas1 Open Access 1 Department of Rheumatology Clinical Immunology and Allergy University of Crete Medical School Voutes 71500 Heraklion Greece laboratory of Flow Cytometry University of Crete Medical School Voutes 71500 Heraklion Greece 3Department of Hematology University of Crete Medical School Voutes 71500 Heraklion Greece Contributed equally Corresponding author Dimitrios T Boumpas boumpasd@ Received 3 Feb 2009 Revisions requested 13 Mar 2009 Revisions received 30 Jun 2009 Accepted 28 Aug 2009 Published 28 Aug 2009 Arthritis Research Therapy 2009 11 R131 doi 86 ar2798 This article is online at http content 11 4 R131 2009 Nakou et al. licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Introduction Bone marrow BM is an immunologically privileged site where activated autoantibody-producing B cells may survive for prolonged periods. We investigated the effect of rituximab anti-CD20 mAb in peripheral blood PB and BM B-cell and T-cell populations in active rheumatoid arthritis RA patients. Methods Active RA patients received rituximab 1 000 mg on days 1 and 15. PB n 11 and BM n 8 aspirates were collected at baseline and at 3 months. We assessed B-cell and T-cell populations using triple-color flow cytometry. Results Rituximab therapy .